Logo image of LFST

LIFESTANCE HEALTH GROUP INC (LFST) Stock Fundamental Analysis

NASDAQ:LFST - Nasdaq - US53228F1012 - Common Stock - Currency: USD

4.345  -0.08 (-1.7%)

Fundamental Rating

3

Overall LFST gets a fundamental rating of 3 out of 10. We evaluated LFST against 103 industry peers in the Health Care Providers & Services industry. LFST scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LFST is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LFST had negative earnings in the past year.
LFST had a positive operating cash flow in the past year.
LFST had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: LFST reported negative operating cash flow in multiple years.
LFST Yearly Net Income VS EBIT VS OCF VS FCFLFST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -1.68%, LFST perfoms like the industry average, outperforming 43.69% of the companies in the same industry.
LFST has a Return On Equity (-2.43%) which is in line with its industry peers.
Industry RankSector Rank
ROA -1.68%
ROE -2.43%
ROIC N/A
ROA(3y)-7.14%
ROA(5y)-11.82%
ROE(3y)-10.38%
ROE(5y)-16.71%
ROIC(3y)N/A
ROIC(5y)N/A
LFST Yearly ROA, ROE, ROICLFST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40

1.3 Margins

LFST does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LFST Yearly Profit, Operating, Gross MarginsLFST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

More info and screens

4

2. Health

2.1 Basic Checks

LFST does not have a ROIC to compare to the WACC, probably because it is not profitable.
LFST has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LFST has been increased compared to 5 years ago.
The debt/assets ratio for LFST is higher compared to a year ago.
LFST Yearly Shares OutstandingLFST Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 100M 200M 300M
LFST Yearly Total Debt VS Total AssetsLFST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of 1.69, we must say that LFST is in the distress zone and has some risk of bankruptcy.
LFST's Altman-Z score of 1.69 is on the low side compared to the rest of the industry. LFST is outperformed by 62.14% of its industry peers.
LFST has a debt to FCF ratio of 2.80. This is a good value and a sign of high solvency as LFST would need 2.80 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 2.80, LFST is doing good in the industry, outperforming 79.61% of the companies in the same industry.
A Debt/Equity ratio of 0.19 indicates that LFST is not too dependend on debt financing.
LFST has a Debt to Equity ratio of 0.19. This is in the better half of the industry: LFST outperforms 67.96% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 2.8
Altman-Z 1.69
ROIC/WACCN/A
WACC8.79%
LFST Yearly LT Debt VS Equity VS FCFLFST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 1.47 indicates that LFST should not have too much problems paying its short term obligations.
LFST's Current ratio of 1.47 is in line compared to the rest of the industry. LFST outperforms 50.49% of its industry peers.
LFST has a Quick Ratio of 1.47. This is a normal value and indicates that LFST is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of LFST (1.47) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.47
Quick Ratio 1.47
LFST Yearly Current Assets VS Current LiabilitesLFST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

LFST shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 79.17%, which is quite impressive.
Looking at the last year, LFST shows a quite strong growth in Revenue. The Revenue has grown by 16.31% in the last year.
Measured over the past years, LFST shows a very strong growth in Revenue. The Revenue has been growing by 42.55% on average per year.
EPS 1Y (TTM)79.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)16.31%
Revenue growth 3Y23.29%
Revenue growth 5Y42.55%
Sales Q2Q%10.83%

3.2 Future

LFST is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 46.55% yearly.
The Revenue is expected to grow by 12.39% on average over the next years. This is quite good.
EPS Next Y68.92%
EPS Next 2Y48.83%
EPS Next 3Y46.55%
EPS Next 5YN/A
Revenue Next Year14.17%
Revenue Next 2Y14.06%
Revenue Next 3Y14.2%
Revenue Next 5Y12.39%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
LFST Yearly Revenue VS EstimatesLFST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B 1.5B 2B
LFST Yearly EPS VS EstimatesLFST Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

LFST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 126.22, which means the current valuation is very expensive for LFST.
LFST's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. LFST is more expensive than 61.16% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.52, LFST is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 126.22
LFST Price Earnings VS Forward Price EarningsLFST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, LFST is valued a bit more expensive than the industry average as 60.19% of the companies are valued more cheaply.
Based on the Price/Free Cash Flow ratio, LFST is valued a bit cheaper than 69.90% of the companies in the same industry.
Industry RankSector Rank
P/FCF 16.59
EV/EBITDA 41.25
LFST Per share dataLFST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates LFST does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as LFST's earnings are expected to grow with 46.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.83%
EPS Next 3Y46.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LFST!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIFESTANCE HEALTH GROUP INC

NASDAQ:LFST (7/18/2025, 10:54:03 AM)

4.345

-0.08 (-1.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners36.53%
Inst Owner Change0%
Ins Owners2.9%
Ins Owner Change2.08%
Market Cap1.69B
Analysts81.33
Price Target8.89 (104.6%)
Short Float %6.36%
Short Ratio4.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)71.99%
Min EPS beat(2)43.98%
Max EPS beat(2)100%
EPS beat(4)4
Avg EPS beat(4)56.42%
Min EPS beat(4)10.6%
Max EPS beat(4)100%
EPS beat(8)5
Avg EPS beat(8)9.87%
EPS beat(12)8
Avg EPS beat(12)7.21%
EPS beat(16)8
Avg EPS beat(16)-4.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.11%
Min Revenue beat(2)-1.94%
Max Revenue beat(2)1.72%
Revenue beat(4)2
Avg Revenue beat(4)0.16%
Min Revenue beat(4)-1.94%
Max Revenue beat(4)1.72%
Revenue beat(8)4
Avg Revenue beat(8)0.56%
Revenue beat(12)6
Avg Revenue beat(12)0.23%
Revenue beat(16)8
Avg Revenue beat(16)0.04%
PT rev (1m)0%
PT rev (3m)-3.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.76%
EPS NY rev (1m)41.17%
EPS NY rev (3m)50.42%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 126.22
P/S 1.32
P/FCF 16.59
P/OCF 13.42
P/B 1.16
P/tB N/A
EV/EBITDA 41.25
EPS(TTM)-0.1
EYN/A
EPS(NY)0.03
Fwd EY0.79%
FCF(TTM)0.26
FCFY6.03%
OCF(TTM)0.32
OCFY7.45%
SpS3.3
BVpS3.75
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.68%
ROE -2.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 7.93%
ROA(3y)-7.14%
ROA(5y)-11.82%
ROE(3y)-10.38%
ROE(5y)-16.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 2.8
Debt/EBITDA 5.68
Cap/Depr 38.82%
Cap/Sales 1.88%
Interest Coverage N/A
Cash Conversion 259.18%
Profit Quality N/A
Current Ratio 1.47
Quick Ratio 1.47
Altman-Z 1.69
F-Score7
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)65.59%
Cap/Depr(5y)98.78%
Cap/Sales(3y)4.95%
Cap/Sales(5y)7.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y68.92%
EPS Next 2Y48.83%
EPS Next 3Y46.55%
EPS Next 5YN/A
Revenue 1Y (TTM)16.31%
Revenue growth 3Y23.29%
Revenue growth 5Y42.55%
Sales Q2Q%10.83%
Revenue Next Year14.17%
Revenue Next 2Y14.06%
Revenue Next 3Y14.2%
Revenue Next 5Y12.39%
EBIT growth 1Y92.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year429.54%
EBIT Next 3Y96.96%
EBIT Next 5YN/A
FCF growth 1Y682.28%
FCF growth 3YN/A
FCF growth 5Y98.76%
OCF growth 1Y202.74%
OCF growth 3Y124.79%
OCF growth 5Y44.39%